Latest news

[Publication scientifique] L’équipe IMATHERA (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM  58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) du #CGFL est ravi d’annoncer la publication de ses travaux de recherche préclinique dans la revue Theranostics en collaboration avec l’équipe #INSERM U1231 (Dr @Carmen Garrido, Pr @Philippe Bonniaud). Ces travaux menés par le Dr @Alexandre Dias et dirigés par le Dr @Pierre-Simon Bellaye démontrent l’intérêt de l’imagerie du collagène pour la détection et la prédiction de la progression de la fibrose pulmonaire et représente un outil d’imagerie non invasif capable de surveiller l’efficacité des thérapies anti-fibrose. Cette étude ouvre la voie à des investigations plus poussées qui pourraient contribuer à l’amélioration de la prise en charge des patients atteints de fibrose pulmonaire idiopathique. Plus d’informations ici : https://www.thno.org/v15p2092.htm

[Scientific publication] The #CGFL‘s IMATHERA team (IMAging and radiation THERapy, #BioSanD – UMS #INSERM 58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) is delighted to announce the publication of its preclinical research work in the journal Theranostics in collaboration with the #INSERM U1231 team (Dr @Carmen Garrido, Pr @Philippe Bonniaud). This work performed by Dr @Alexandre Dias and led by Dr @Pierre-Simon Bellaye demonstrates the value of collagen imaging for detecting and predicting the progression of pulmonary fibrosis, and represents a non-invasive imaging tool capable of monitoring the efficacy of anti-fibrosis therapies. This study paves the way for further investigations that could contribute to improving the management of patients with idiopathic pulmonary fibrosis. Read more here: https://www.thno.org/v15p2092.htm

#Research, #CGFL, #IPF, #Fondation du souffle, #Theranostics

[Publication scientifique] L’équipe IMATHERA (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM  58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) du #CGFL est ravi d’annoncer la publication de ses travaux de recherche préclinique dans la revue Thorax en collaboration avec l’équipe #INSERM U1231 (Dr @Carmen Garrido, Pr @Philippe Bonniaud). Ces travaux dirigés par le Dr @Pierre-Simon Bellaye démontrent l’intérêt de l’imagerie des macrophages de type 2 pour la détection et la prédiction de la progression de la fibrose pulmonaire et représente un outil d’imagerie non invasif capable de surveiller l’efficacité des thérapies anti-fibrotiques. Cette étude ouvre la voie à des investigations plus poussées qui pourraient contribuer à l’amélioration de la prise en charge des patients atteints de fibrose pulmonaire idiopathique. Plus d’informations ici : https://thorax.bmj.com/content/thoraxjnl/early/2024/07/20/thorax-2023-221168.full.pdf

[Scientific publication] The #CGFL‘s IMATHERA team (IMAging and radiation THERapy, #BioSanD – UMS #INSERM 58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) is delighted to announce the publication of its preclinical research work in the journal Thorax in collaboration with the #INSERM U1231 team (Dr @Carmen Garrido, Pr @Philippe Bonniaud). This work led by Dr @Pierre-Simon Bellaye demonstrates the value of type 2 macrophage imaging for detecting and predicting the progression of pulmonary fibrosis, and represents a non-invasive imaging tool capable of monitoring the efficacy of anti-fibrosis therapies. This study paves the way for further investigations that could contribute to improving the management of patients with idiopathic pulmonary fibrosis. Read more here: https://thorax.bmj.com/content/thoraxjnl/early/2024/07/20/thorax-2023-221168.full.pdf

#Research, #CGFL, #IPF, #Fondation du souffle, #Theranostics

[Recherche] Toute l’équipe de la plateforme IMATHERA (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM  58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) du #CGFL est fière d’annoncer sa participation en tant que partenaire à deux projets de recherche préclinique financés par l’ANR :

– Le projet SUPRALABEL, dirigé par @Victor Goncalves (#ICMUB – UMR CNRS 6302) en partenariat avec @Pierre-Simon Bellaye (#CGFL) centré sur l’évaluation d’une stratégie innovante d’imagerie de la fibrose pulmonaire.

– Le projet Nose To brain N2B – Dirigé par @Didier Boquet (#CEA, Saclay) en collaboration avec @Franck Denat (#ICMUB – UMR CNRS 6302) et @Bertrand Collin (#CGFL, #ICMUB – UMR CNRS 6302) centré sur l’évaluation d’une stratégie d’injection intranasale de thérapie ciblant les métastases cérébrales.

[Research] The entire IMATHERA platform team (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM 58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) at the #CGFL is proud to announce its participation as a partner in two preclinical research projects funded by the ANR :

– The SUPRALABEL project, led by @Victor Goncalves (#ICMUB – UMR CNRS 6302) in partnership with @Pierre-Simon Bellaye (#CGFL) focused on the evaluation of an innovative imaging strategy for pulmonary fibrosis.

– The Nose To brain N2B project – led by @Didier Boquet (#CEA, Saclay) in collaboration with @Franck Denat (#ICMUB – UMR CNRS 6302) and @Bertrand Collin (#CGFL, #ICMUB – UMR CNRS 6302) – focused on evaluating an intranasal injection strategy for therapy targeting brain metastases.

Toute l’équipe de la plateforme IMATHERA (IMAgerie préclinique et THErapie par les radiations ionisantes, #BioSanD – UMS #INSERM  58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) du #CGFL est heureuse d’annoncer l’obtention de la certification ISO9001. Cela démontre son engagement pour l’amélioration continue de la qualité en interne et au service de ses clients et partenaires. IMATHERA remercie particulièrement @Maria Saunié et @Erwan Petit (service qualité #CGFL) et @Alex Helbling (chef de projet et responsable qualité IMATHERA).

The entire team at the #CGFL‘s IMATHERA platform (IMAging and radiation THERapy, #BioSanD – UMS #INSERM 58, Dr @Bertand Collin, #ICMUB – UMR CNRS 6302) is delighted to announce that it has obtained ISO9001 certification. It demonstrates its commitment to continuous improvement in order to best meet customer expectations and guarantee the quality of its own and partnered research. IMATHERA would particularly like to thank @Maria Saunié and @Erwan Petit (#CGFL quality department) and @Alex Helbling (IMATHERA project manager and quality manager).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy) targeting HER2, in a HER2-low context, could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of these patients. This project will be driven in collaboration with ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine Paul (École Pratique des Hautes Études – Université PSL) and in collaboration with the ICMUB (Dr Goze Christine) and Besançon University Hospital (Dr Doussot Alexandre).

​

Probes developed in this prject will be tested for FGS in various preclinical models mimicking human pathology, such as orthotopic models of colon and pancreatic cancers, but also models mimicking the formation of liver metastases or peritoneal carcinomatosis. The expected results of this project are fine visualisation of tumours before surgery (SPECT imaging) and more accurate detection by fluorescence, enabling the extent of resection to be minimised. Finally, it will be possible to detect the absence of recurrence using this compound a few weeks after surgery (SPECT).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics) in colorectal and gastric cancers that could represent an innovative approach to overcome the current problems and thus improve the diagnosis and therapeutic management of patients.

This project will be driven by Oncodesign Precision Medicine (OPM, Dijon) with a third parter, ICMUB (Dr Franck DENAT, ICMUB – UMR CNRS 6302).

IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) was present at the “5ème Journées Scientifiques du GDR Agents d’Imagerie Moléculaire (GDR AIM)” in Paris. Romain Fontaine-Tuffery (ICMUB – UMR CNRS 6302/CGFL) presented his research work as part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) on the synthesis of fluorinated metal porphyrin platforms for PET imaging and photodynamic therapy. This work is under the direction of Dr Bertrand Collin (CGFL/ICMUB) and Dr Richard Decreau (Associate Professor, ICMUB – UMR CNRS 6302).

IMATHERa (CGFL, Dr Bertand Collin, ICMUB – UMR CNRS 6302) was present at the “Journées de recherche respiratoires (J2R)” in Tours. Dr Alexandre Dias (CGFL) presented his research work as part of the HYMAGE-IPF project (ANR-20-CE17-0005) on the development of a theranostic strategy targeting Gp96 in pulmonary fibrosis. This work, under the direction of Dr Pierre-Simon Bellaye (CGFL), was carried out in collaboration with Pr Philippe Bonniaud’s (CHU de Dijon – INSERM U1231, HSP-pathies) team led by Dr Carmen Garrido (INSERM U1231, HSP-pathies).

IMATHERa (CGFL) was present at the European Congress of Nuclear Medicine (EANM) in Vienna. Drs Alan Courteau and Bertrand Collin (CGFL / ICMUB – UMR CNRS 6302) presented their research work part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) program on preclinical multi-animal PET/MRI imaging and preclinical theranostic PET imaging of CD30-positive cancers with [Zr89]Zr-DFO-Brentuximab vedotin, respectively.